Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

GSK, along with several other drug manufacturing companies, had received a warning letter from the Federal Trade Commission ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

AZ has confirmed that the US regulator issued a complete response letter (CRL) for PT010, a triple therapy for COPD that would compete with GSK’s already-marketed Trelegy. A spokesman for AZ tol ...

GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the group. “​​At this time, we believe there are other areas ...

GSK GSK-1.51%decrease; red down pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

U.S. equity markets reached all-time highs during the third quarter of 2024 with the S&P 500 posting its best year-to-date performance in nearly 30 years.